Clinical Research Informer

Pfizer to Present Latest Scientific Advancements from Its Industry-Leading Portfolio at the ESMO Virtual Congress 2020

The Pharma Data

SEPTEMBER 10, 2020

NEW YORK–(BUSINESS WIRE)– Pfizer Inc. Data to be presented include findings from the Phase 3 CROWN study of LORBRENA ® (lorlatinib)* in first-line ALK-positive non-small cell lung cancer (NSCLC), building on Pfizer’s extensive heritage in precision medicine research. Grivas P. . Ascierto P. . .

Production

Production Medicine Containment Development

Pfizer and BioNTech Initiate Phase 1/2 Study of First mRNA-based Shingles Vaccine Program

Pfizer

FEBRUARY 9, 2023

Pfizer and BioNTech Initiate Phase 1/2 Study of First mRNA-based Shingles Vaccine Program kimkevin Thu, 02/09/2023 - 15:05 Pfizer and BioNTech Initiate Phase 1/2 Study of First mRNA-based Shingles Vaccine Program Friday, February 10, 2023 - 06:45am Share Phase 1/2 trial will enroll up to 900 healthy U.S.

Vaccination

Vaccination Vaccine Clinical Trials Clinical Trials

Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine

The Pharma Data

NOVEMBER 20, 2020

and plan to submit applications immediately to other regulatory agencies around the world. NEW YORK & MAINZ, Germany–(BUSINESS WIRE)–Friday, November 20, 2020 — Pfizer Inc. . NEW YORK & MAINZ, Germany–(BUSINESS WIRE)–Friday, November 20, 2020 — Pfizer Inc.

Vaccination

Vaccination Vaccine Clinical Trials Clinical Trials

Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19

The Pharma Data

DECEMBER 1, 2020

NEW YORK & MAINZ, Germany–( BUSINESS WIRE )– Pfizer Inc. Pfizer and BioNTech are anticipating further regulatory decisions across the globe in the coming days and weeks and are ready to deliver vaccine doses following potential regulatory authorizations or approvals. 2, 2020 07:05 UTC.

Vaccination

Vaccination Vaccine Manufacturing Clinical Trials

U.S. FDA Extends Review of Pfizer’s New Drug Application for PAXLOVID™

Pfizer

DECEMBER 20, 2022

FDA Extends Review of Pfizer’s New Drug Application for PAXLOVID™. FDA Extends Review of Pfizer’s New Drug Application for PAXLOVID™. Pfizer oral treatment remains available to eligible U.S. Pfizer oral treatment remains available to eligible U.S. NEW YORK, December 20, 2022 -- Pfizer Inc.

Drugs

Drugs Licensing Licensing Containment

U.S. FDA ACCEPTS FOR PRIORITY REVIEW

The Pharma Data

FEBRUARY 25, 2021

FDA ACCEPTS FOR PRIORITY REVIEW PFIZER’S APPLICATION FOR TICOVAC (TICK-BORNE ENCEPHALITIS VACCINE). NEW YORK–(BUSINESS WIRE)– Pfizer Inc. Global President, Vaccines, Pfizer Inc. “If More than 40 years of experience with the Pfizer TBE vaccine exist outside the U.S.,

Vaccination

Vaccination Vaccine Clinical Trials Clinical Trials

Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE®

The Pharma Data

JUNE 2, 2022

Myovant Sciences (NYSE: MYOV) and Pfizer Inc. Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA) for MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 Chief Medical Officer of Myovant Sciences, Inc. “We NYSE: PFE) announced today that the U.S.

Drugs

Drugs Hormones Development Medicine

FIRST-LINE TREATMENT FOR ALK-POSITIVE METASTATIC LUNG CANCER

The Pharma Data

MARCH 3, 2021

Food and Drug Administration (FDA) approved Pfizer Inc.’s s (NYSE: PFE) supplemental New Drug Application (sNDA) for LORBRENA ® (lorlatinib), expanding the indication to include first-line treatment of people with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). About the CROWN Trial.

FDA Approval

FDA Approval Hormones Trials Medicine

Data Published in New England Journal of Medicine Shows Pfizer’s Tofacitinib Meets Primary Endpoint in Brazilian Study in Patients Hospitalized with COVID-19 Pneumonia

The Pharma Data

JUNE 16, 2021

NEW YORK–(BUSINESS WIRE)– Pfizer Inc. The trial was a research collaboration between Pfizer and the ARO from the Hospital Israelita Albert Einstein in Sao Paulo, Brazil, which was the trial coordinating center. to 0.97; p=0.04). Chief Medical Officer, Pfizer Inflammation & Immunology. “As

Medicine

Medicine Clinical Trials Clinical Trials Trials

Safety Recommendation on Janus kinase (JAK) Inhibitors Issued in the European Union

Pfizer

OCTOBER 28, 2022

New York, October 28, 2022 — Pfizer Inc. 1,2,3 As the developer of tofacitinib, Pfizer is committed to advancing the science of Janus kinase inhibition and enhancing understanding of tofacitinib through robust clinical development programs in the treatment of immune-mediated inflammatory conditions. Pfizer Inc.:

Clinical Trials

Clinical Trials Clinical Trials Vaccination Vaccine

Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza

Pfizer

DECEMBER 8, 2022

Pfizer and BioNTech Receive U.S. Pfizer and BioNTech Receive U.S. NEW YORK and MAINZ, GERMANY, DECEMBER 9, 2022 — Pfizer Inc. INDICATION & AUTHORIZED USE Pfizer-BioNTech COVID-19 Vaccine, Bivalent, (Original and Omicron BA.4/BA.5) Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5)

Vaccination

Vaccination Vaccine Clinical Trials Clinical Trials

Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19

Pfizer

NOVEMBER 2, 2022

Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19. Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19. NEW YORK and MAINZ, GERMANY, November 3, 2022 — Pfizer Inc.

Vaccination

Vaccination Vaccine Clinical Trials Clinical Trials

MYFEMBREE® FOR THE MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED.

The Pharma Data

SEPTEMBER 10, 2021

Myovant Sciences (NYSE: MYOV) and Pfizer Inc. Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA) for MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 Chief Medical Officer of Myovant Sciences, Inc. “If NYSE: PFE) today announced that the U.S.

Hormones

Hormones FDA Approval Drugs Development

COVID-19 Pandemic Coverage

XTalks

SEPTEMBER 14, 2020

These companies include Moderna, a US biotech company which has formed a partnership with the National Institute of Allergy and Infectious Diseases (NIAID), Oxford University who has partnered with AstraZeneca, and Johnson & Johnson, Merck and Pfizer. Pfizer and BioNTech’s COVID-19 Vaccine. billion in June. ECONOMIC IMPACT: Canada.

Vaccination

Vaccination Vaccine Antibody Life Science

Clinical Research Informer

Pfizer to Present Latest Scientific Advancements from Its Industry-Leading Portfolio at the ESMO Virtual Congress 2020

Pfizer and BioNTech Initiate Phase 1/2 Study of First mRNA-based Shingles Vaccine Program

Trending Sources

Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine

Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19

U.S. FDA Extends Review of Pfizer’s New Drug Application for PAXLOVID™

U.S. FDA ACCEPTS FOR PRIORITY REVIEW

Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE®

FIRST-LINE TREATMENT FOR ALK-POSITIVE METASTATIC LUNG CANCER

Data Published in New England Journal of Medicine Shows Pfizer’s Tofacitinib Meets Primary Endpoint in Brazilian Study in Patients Hospitalized with COVID-19 Pneumonia

Safety Recommendation on Janus kinase (JAK) Inhibitors Issued in the European Union

Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza

Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19

MYFEMBREE® FOR THE MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED.

COVID-19 Pandemic Coverage

Stay Connected